Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Soleno Therapeutics Inc (Soleno Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product is diazoxide choline (DCCR) for the treatment of hyperphagia in adults and children. The company’s products functions as an ATP-sensitive potassium (KATP) channel activator, with activity in the brain, pancreas, and adipose tissue, addressing appetite regulation, insulin secretion, and fat metabolism. It markets its products under VyKat brand name. Soleno is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
Suite 400, 100 Marine Parkway, Redwood City, California, 94065
Website
soleno.life
Telephone
1 650 2138444
No of Employees
182
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$190.4M
Soleno Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline Product: | Vykat |
| Diazoxide Choline Controlled Release (DCCR) Tablets |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Regulatory Approval | In June, the company secured FDA approval for its investigational drug, DCCR for the treatment of Glycogen Storage Disease Type 1a. |
| 2021 | Contracts/Agreements | In February, the company signed a collaboration agreement with Vanderbilt University to discover and develop novel K(ATP) channel activators for treatment of rare diseases. |
| 2017 | Contracts/Agreements | In December, Soleno Therapeutics and its subsidiary, Capnia, Inc., entered into a joint venture agreement with OptAsia Healthcare Limited for the development and commercialization of Capnia’s Sensalyze technology. |
Competitor Comparison
| Key Parameters | Soleno Therapeutics Inc | Acadia Pharmaceuticals Inc | Rhythm Pharmaceuticals Inc | Neuren Pharmaceuticals Ltd | OT4B |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Australia | France |
| City | Redwood City | San Diego | Boston | Camberwell | Toulouse |
| State/Province | California | California | Massachusetts | Victoria | Midi Pyrenees |
| No. of Employees | 182 | 796 | 414 | - | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Anish Bhatnagar | Chairman; Chief Executive Officer | Executive Board | 2025 | 57 |
| Jennifer Fulk | Chief Financial Officer | Senior Management | 2026 | - |
| Patricia Hirano | Senior Vice President-Regulatory Affairs | Senior Management | 2019 | 58 |
| Kristen Yen | Senior Vice President-Global Clinical Operations and Patient Advocacy | Senior Management | 2006 | 56 |
| Meredith Manning | Chief Commercial Officer | Senior Management | - | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer